Top articles of the week from The American Journal of Pharmacy Benefits.
Increasing expression of REV-ERB observed to decrease LDL cholesterol.
Real-world evidence suggests SGLT-2 can reduce all-cause mortality in diabetes patients.
Safinamide approved as an add-on treatment for patients with Parkinson’s disease when their medications are not working well.
Study suggests Medicare reform to help patients predict monthly medication costs.
The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival.
Bavencio (avelumab) is indicated to treat metastatic Merkel cell carcinoma.
View More >
Increased screen time observed to be associated with adiposity.
From the Journals
Having the right evidence, using high-value care, and developing strong incentives to improve payment and delivery systems are among the ways we can improve healthcare.
This analytic model assessed the per-woman cost differences between the use of 2 levonorgestrel-releasing intrauterine devices, from a US payer perspective.
The characteristics of patients who require increases in their basal insulin dose were compared with those requiring no increase following conversion between basal insulin analogues.
Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).
In our quest to identify the areas and activities that show the greatest positive impact and value in care and outcomes, we must aim to not let good science and evidence get away from us, particularly when considering vaccination.
A new ophthalmic formulation of bimatoprost was found to improve adherence and persistence compared with the original formulation of bimatoprost.
Although naloxone delivery devices are proven to reduce opioid overdoses, challenges persist in increasing the use of these devices in the community setting.